Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

GLMD Galmed Pharmaceuticals Ltd

1,895

0,0071 (0,38%)

11 Mär 2025 - Geschlossen

Verzögert um 15 Minuten

Form EFFECT - Notice of Effectiveness

Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
Von Feb 2025 bis Mär 2025

Click Here for more Galmed Pharmaceuticals Charts.

Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
Von Mär 2024 bis Mär 2025

Click Here for more Galmed Pharmaceuticals Charts.

News Galmed Pharmaceuticals Ltd

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Dienstag 18 Februar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Dienstag 7 Januar 2025 (2 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 14 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Form F-3 - Registration statement by foreign private issuers
Donnerstag 14 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 14 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Montag 28 Oktober 2024 (4 Monate vor) • Edgar (US Regulatory)

Form F-1 - Registration statement for certain foreign private issuers
Montag 21 Oktober 2024 (5 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 21 Oktober 2024 (5 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 15 Oktober 2024 (5 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 25 September 2024 (5 Monate vor) • Edgar (US Regulatory)

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Mittwoch 25 September 2024 (5 Monate vor) • PR Newswire (US)

Weitere Galmed Pharmaceuticals Ltd News-Artikel

Vontobel Financial Produ...

Societe Generale Effekten

BlackRock Asset Manageme...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen